Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2012 Jul;64(7):1001-10.
doi: 10.1002/acr.21625.

Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis

Esi Morgan DeWitt  1 , Yukiko Kimura, Timothy Beukelman, Peter A Nigrovic, Karen Onel, Sampath Prahalad, Rayfel Schneider, Matthew L Stoll, Sheila Angeles-Han, Diana Milojevic, Kenneth N Schikler, Richard K Vehe, Jennifer E Weiss, Pamela Weiss, Norman T Ilowite, Carol A Wallace; Juvenile Idiopathic Arthritis Disease-specific Research Committee of Childhood Arthritis Rheumatology and Research Alliance
Collaborators, Affiliations
Multicenter Study

Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis

Esi Morgan DeWitt et al. Arthritis Care Res (Hoboken). 2012 Jul.

Abstract

Objective: There is wide variation in therapeutic approaches to systemic juvenile idiopathic arthritis (JIA) among North American rheumatologists. Understanding the comparative effectiveness of the diverse therapeutic options available for treatment of systemic JIA can result in better health outcomes. The Childhood Arthritis and Rheumatology Research Alliance (CARRA) developed consensus treatment plans and standardized assessment schedules for use in clinical practice to facilitate such studies.

Methods: Case-based surveys were administered to CARRA members to identify prevailing treatments for new-onset systemic JIA. A 2-day consensus conference in April 2010 employed modified nominal group technique to formulate preliminary treatment plans and determine important data elements for collection. Followup surveys were employed to refine the plans and assess clinical acceptability.

Results: The initial case-based survey identified significant variability among current treatment approaches for new-onset systemic JIA, underscoring the utility of standardized plans to evaluate comparative effectiveness. We developed 4 consensus treatment plans for the first 9 months of therapy, as well as case definitions and clinical and laboratory monitoring schedules. The 4 treatment regimens included glucocorticoids only, or therapy with methotrexate, anakinra, or tocilizumab, with or without glucocorticoids. This approach was approved by >78% of the CARRA membership.

Conclusion: Four standardized treatment plans were developed for new-onset systemic JIA. Coupled with data collection at defined intervals, use of these treatment plans will create the opportunity to evaluate comparative effectiveness in an observational setting to optimize initial management of systemic JIA.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Glucocorticoid treatment plan. Note: 1Intravenous methylprednisolone (IV MP) pulses are one dose weekly. 2Patients who started with rapid taper may be off prednisone.
Figure 2
Figure 2
Methotrexate treatment plan. Notes: 1Intravenous methylprednisolone (IV MP) pulses are one dose weekly. 2Patients who started with rapid taper may be off prednisone. 3If condition worsens follow “Unchanged, Worse” pathway. 4If patient is intolerant of methotrexate, discontinue and add additional therapy.
Figure 3
Figure 3
Anakinra treatment plan. Notes: 1Intravenous methylprednisolone (IV MP) pulses are one dose weekly. 2Patients who started with rapid taper may be off prednisone. 3If condition worsens or patient is intolerant of anakinra follow “Unchanged, Worse” pathway.
Figure 4
Figure 4
Tocilizumab treatment plan. Notes: 1 Intravenous methylprednisolone (IV MP) pulses are one dose weekly. 2Patients who started with rapid taper may be off prednisone. 3If condition worsens or patient is intolerant of tocilizumab follow “Unchanged, Worse” pathway.
See this image and copyright information in PMC

Comment in

References

    1. Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial) Ann Rheum Dis. 2011 May;70(5):747–754. - PMC - PubMed
    1. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371(9617):998–1006. - PubMed
    1. FDA. FDA approves Actemra to treat rare form of juvenile arthritis. Silver Spring, MD: US Food and Drug Administration; U.S. Department of Health and Human Services; 2011. Apr 15,
    1. Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011 Apr;63(4):465–482. - PMC - PubMed
    1. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford) 2002;41(12):1428–1435. - PubMed

Publication types

LinkOut - more resources